Skip to main content

Table 2 HDAC6 inhibitors in clinical trials for cancer

From: Histone deacetylase 6 in cancer

NCT numbers

Agent

Other agents

Inclusion

Phase

Start

End

Enrollment

NCT02935790

ACY-241

Nivolumab

Malignant melanoma

I

2016.10

2017.8

1

Ipilimumab

NCT02635061

ACY-241

Nivolumab

NSCLC

I

2015.12

2018.5

41

NCT01583283

ACY-1215

Lenalidomide

Multiple myeloma

I/II

2012.7

2018.11

38

Dexamethasone

NCT01323751

ACY-1215

–

Multiple myeloma

I/II

2011.3

2017.4

120

NCT02091063

ACY-1215

–

Lymphoma

I/II

2014.3

2017.5

40

Lymphoid malignancies

NCT02632071

ACY-1215

Nab-paclitaxel

Metastatic breast cancer

I

2015.12

2018.2

24

Breast carcinoma

NCT03008018

KA2507

–

Solid tumor

I

2017.8

2019.3

30

  1. NSCLS non-small cell lung cancer